M.Satyanarayana Reddy

Net Worth

$2.502B

0% (24h)

Dr. M. Satyanarayana Reddy, often referred to as Dr. MSN, is a prominent figure in the Indian pharmaceutical industry, recognized for his entrepreneurial success and contributions to affordable healthcare. With a current net worth of $2.5 billion, Dr. Reddy's wealth stems from his founding and leadership of MSN Group, a rapidly growing pharmaceutical company headquartered in Hyderabad, India. His career began as a chemist, evolving into a successful research career within the pharmaceutical sector before he established MSN Laboratories in 2003. His achievements include developing affordable generic medicines and establishing 16 manufacturing facilities across India, Myanmar, and the USA, contributing to global access to essential medications. He is known for manufacturing Favipiravir, a low-cost version of a Covid-19 drug and holds numerous patents.

The Full Dossier

Early Life

Dr. Manne Satyanarayana Reddy, or Dr. MSN, was born in Telangana, India. He completed his education in the local area and later pursued a Ph.D. in Organic Chemistry from Osmania University. He embarked on his career in the pharmaceutical industry in 1990.

Rise to Success

Before his entrepreneurial journey, Dr. Reddy gained experience in the pharmaceutical industry, holding positions such as Head of Research and Development at leading Indian pharmaceutical companies. In 2003, he founded MSN Laboratories with a vision to make high-quality medicines accessible and affordable.

Key Business Strategies

MSN Group's strategy involves a focus on research and development, leading to numerous patents and the ability to manufacture generic versions of essential medicines, including a low-cost version of a COVID-19 drug called Favipiravir. The company expanded its manufacturing footprint to include facilities in India, Myanmar, and the USA.

Philanthropy

Dr. Reddy has been involved in philanthropic efforts, including donating medical supplies during the pandemic.

Career Timeline

2020

Favilow Production

MSN started making a low-priced version of the Covid-19 drug Favipiravir under the brand name Favilow.

2003

Founded MSN Laboratories

Established MSN Laboratories with a mission to make high-quality medicines affordable.

1990

Pharmaceutical Career

Began a career as a chemist, building a successful research career in the pharma industry.

Philanthropic Impact

Healthcare$0.63M

COVID-19 Relief

Donated medical supplies and equipment to fight the pandemic.